Drug Profile
Research programme: antibacterials - Albany Molecular Research/Merck
Alternative Names: Antibacterials research programme - Albany Molecular Research/MerckLatest Information Update: 08 Feb 2017
Price :
$50
*
At a glance
- Originator Albany Molecular Research Inc
- Developer Albany Molecular Research Inc; Cubist Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 24 May 2006 No development reported - Preclinical for Bacterial infections in USA (unspecified route)
- 24 Aug 2001 Preclinical development for Bacterial infections in USA (Unknown route)